Marion T. Weigel - Concepedia

Author

Marion T. Weigel

University Hospital Schleswig-Holstein

Also Known As

M Weigel, M. T. Weigel, M. Weigel, M.T. Weigel, Marion T Weigel, Marion T. Weigel, Marion Tina Weigel, Marion Weigel

Publications

1.4K

Citations

H-Index

Concepts

All Affiliations

University Hospital Schleswig-Holstein University of Lübeck RWTH Aachen University Royal Marsden Hospital Breast Cancer Now

About

Marion T. Weigel is an author at University Hospital Schleswig-Holstein specializing in medicine, pharmacology, and breast cancer.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	10	10	353
2	Health Sciences	1	1	16
3	Social Sciences	1	1	24
4	Anatomy	1	1	24
5	Biomolecular Engineering	1	1	16

Marion T. Weigel

Publications

678

Citations

H-Index

Page 1

	Year	Citations
Phase II study of MTX-HSA in combination with Cisplatin as first line treatment in patients with advanced or metastatic transitional cell carcinoma Claus Bolling, T. Graefe, C. Lübbing, Investigational New Drugs UrologyMedicinePhase Ii StudyPathologyImmune Checkpoint Inhibitor	2006	77
Differential expression of MMP-2, MMP-9 and PCNA in endometriosis and endometrial carcinoma Marion T. Weigel, Julia Krämer, Christian Schem, European Journal of Obstetrics & Gynecology and Reproductive Biology Tumoral PathologyDifferential ExpressionPathologyGynecologyEndometrial Carcinoma	2011	61
In vitro effects of imatinib mesylate on radiosensitivity and chemosensitivity of breast cancer cells Marion T. Weigel, Linda Dahmke, Christian Schem, BMC Cancer	2010	56
Progression-Free Survival in Ovarian Cancer Is Reflected in Epigenetic DNA Methylation Profiles Dirk Bauerschlag, Ole Ammerpohl, Karen Bräutigam, Oncology	2011	52
Preclinical and clinical studies of estrogen deprivation support the PDGF/Abl pathway as a novel therapeutic target for overcoming endocrine resistance in breast cancer Marion T. Weigel, Zara Ghazoui, Anita K. Dunbier, Breast Cancer Research	2012	43
Enhanced expression of the PDGFR/Abl signaling pathway in aromatase inhibitor-resistant breast cancer Marion T. Weigel, Susana Banerjee, Mónica Arnedos, Annals of Oncology Breast OncologyEndocrine-related CancerMedicineEnhanced ExpressionBreast Cancer	2012	43
Pre-surgical study of the biological effects of the selective cyclo-oxygenase-2 inhibitor celecoxib in patients with primary breast cancer Lesley‐Ann Martin, Giles Davies, Marion T. Weigel, Breast Cancer Research and Treatment Breast OncologyOncologyBiological EffectsMedicinePathology	2010	42
Effectiveness and molecular interactions of the clinically active mTORC1 inhibitor everolimus in combination with tamoxifen or letrozole in vitro and in vivo Lesley‐Ann Martin, Sunil Pancholi, Ian Farmer, Breast Cancer Research	2012	33
Combination of imatinib and vinorelbine enhances cell growth inhibition in breast cancer cells via PDGFR β signalling Marion T. Weigel, Ivo Meinhold‐Heerlein, Dirk Bauerschlag, Cancer Letters Breast OncologyPdgfr βMedicineBreast Cancer CellsVinorelbine Enhances	2008	29
Novel treatment of ovarian cancer cell lines with Imatinib mesylate combined with Paclitaxel and Carboplatin leads to receptor-mediated antiproliferative effects Christoph Mundhenke, Marion T. Weigel, Klarissa Hanja Stürner, Journal of Cancer Research and Clinical Oncology MedicineNovel TreatmentPharmacologyGynecologyReceptor-mediated Antiproliferative Effects	2008	27

Page 1